-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Cigna Group (CI) Below Fair Value On Mixed Q3 2026 Earnings?

Simply Wall St·11/16/2026 01:19:37
Listen to the news

The Cigna Group (CI) is back in focus for investors after its third quarter 2026 earnings release, which reported higher sales and revenue alongside lower quarterly net income and earnings per share.

Recent trading shows Cigna Group shares edging higher over the past week. The 90 day share price return of 7.87% points to improving momentum, even though the 30 day move slipped 1.75%, and the 1 year total shareholder return of 12.63% reflects steadier long term gains.

Spot similar health insurers showing strong revenue scale and shifting earnings trends by scanning our curated list of 29 resilient stocks with low risk scores.

Cigna Group trades below analyst targets and appears to carry a steep implied discount to intrinsic value after the mixed quarter and modest share gain. Is that a pricing error, or is the market flagging real risks in the earnings trend?

Most Popular Narrative: 53% Undervalued

Cigna Group closed at $297.00, compared with a narrative fair value estimate of $636.28. This frames a sharp valuation gap that the narrative says only makes sense after scrutinising the risks in detail. According to John_Eric, an investor in the Simply Wall St Community who wrote the narrative, the investment case hinges on treating Cigna like an insurance policy that must be underwritten rather than a headline discount to be taken at face value.

Cigna offers a 55.3% raw discount because the market is not valuing growing earnings in isolation. It is pricing political hostility toward PBMs, restrictions on Express Scripts, uncertainty around automated claims review, declining customer counts, uneven cash conversion, and the possibility that today’s most profitable practices may not remain tomorrow’s permissible ones.

After pricing the uncertainty, the actionable margin of safety falls to 24.9%, which is one-tenth of a point below our line.

See why 6 investors see Cigna Group as 53% undervalued.

The narrative leans heavily on Cigna Group’s role in pharmacy benefit management, the 10 year regulatory monitoring period around Express Scripts, and the PxDx litigation as reasons to treat the raw discount with caution rather than enthusiasm. It ties that back to an underwriting style framework, where a large apparent margin of safety only becomes actionable if the investor is comfortable with how regulation, customer trends, cash conversion and leadership changes interact with Cigna’s existing earnings power and scale.

Result: Fair Value of $636.28 (UNDERVALUED)

Still, Cigna Group’s story could change fast if the PxDx litigation escalates or if the decade of Express Scripts monitoring begins to compress PBM economics.

Find out about the key risks to this Cigna Group narrative.

Next Steps

If the mixed tone around Cigna Group leaves you unsure, take a closer look at both sides of the ledger and move quickly to frame your own stance with 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Cigna Group?

Do not stop your research at a single health insurer when a broader watchlist could reveal opportunities that fit your risk, income, and valuation preferences.